Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
PHENTOLAMINE MESYLATE
SEPTODONT
V03AB36
PHENTOLAMINE
0.4MG
SOLUTION
PHENTOLAMINE MESYLATE 0.4MG
SUBMUCOSAL
10X1.7ML/50X1.7ML
Prescription
Non-Selective Alfa-Adrenergic Blocking Agents
Active ingredient group (AIG) number: 0107611003; AHFS:
APPROVED
2014-02-26
COPYRIGHT 2012 - 2013 SEPTODONT Page 1 of 17 PRODUCT MONOGRAPH PR ORAVERSE PHENTOLAMINE MESYLATE INJECTION HOUSE STANDARD PHENTOLAMINE MESYLATE INJECTION, 0.4MG/1.7ML _ _ _ _ Alpha-adrenoreceptor blocker _For Intraoral Submucosal Injection Only _ Sponsor: Manufacturer: Septodont SAS Novocol Pharmaceutical of Canada, Inc. 58 Rue Du Pont De Creteil 25 Wolseley Court, Saint-Maur Des Fosses Cambridge, Ontario, France 94100 N1R 6X3 DATE OF PREPARATION: FEBRUARY 24, 2014 SUBMISSION CONTROL NO: 157450 COPYRIGHT 2012 - 2013 SEPTODONT Page 2 of 17 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................................... 3 SUMMARY PRODUCT INFORMATION .................................................................................................... 3 INDICATIONS AND CLINICAL USE.......................................................................................................... 3 CONTRAINDICATIONS ............................................................................................................................... 3 WARNINGS AND PRECAUTIONS ............................................................................................................. 3 ADVERSE REACTIONS ............................................................................................................................... 4 DRUG INTERACTIONS ................................................................................................................................ 6 DOSAGE AND ADMINISTRATION ............................................................................................................ 7 OVERDOSAGE .............................................................................................................................................. 8 ACTION AND CLINICAL PHARMACOLOGY .......................................................................................... 8 STORAGE AND STABILITY ................................................................ Prečítajte si celý dokument